In a historic first, the FDA has approved an option injectable PrEP, Apretude (cabotegravir).

We’re proud to have served as a key site in the clinical trials for this milestone drug toward ending the HIV epidemic, with the hard-working team of Mills Clinical Research in West Hollywood. As news circulates of this landmark event, we spoke with MHF Chief Pharmacy Officer, Dr. Vishal Gandhi, PharmD, RPh, on some frequently asked questions about this upcoming option for HIV prevention.

Is Apretude available now?

VG: "It is not available to order yet, and we don't quite know exactly when it will be available for purchase. However, we are working with representatives from ViiV and our drug wholesalers to be sure we continually have up-to-date information."

How will Apretude be covered through insurance?

VG: ""We currently do not know if this will be covered under a patient's medical or pharmacy benefit. There are numerous plans out there, and with Cabenuva, we have seen it covered under both the medical and pharmacy benefit. For Apretude, it will likely depend on each individual's health insurance plan. It often takes health plans a few months to decide if and how they want to cover a new medication.”

Will a PA (Prior Authorization) be required to begin Apretude?

VG: "We have no indication if a PA will be required. However, with our experience with new medications that have a cheaper alternative available, it would not surprise us if we are asked to submit a PA."

How will the cost of Apretude compare to other PrEP options?

VG: "The cost a patient may incur will be highly dependent on their health plan. Each health plan will have different coverages, copay requirements, deductibles, etc. We will do our best to minimize the cost to our patients by trying to obtain PAs or copay assistance to help reduce the financial burden."

Additional information on Apretude will be provided to patients as soon as it becomes available. Read more about Apretude and the new FDA approval on FDA.gov.